Document M6jgM8Y8LdV7aG80yRvYRV5y
AR226-3211
TRADE SECRET
Study Title H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
Supplement No. 1
Laboratory Project ID: DuPont-2923
AUTHOR: Carol Finlay, B.A.
STUDY COMPLETED ON: July 27, 2000
SUPPLEMENT NO. 1 COMPLETED ON: December 13, 2001
PERFORMING LABORATORY:
E.I. du Font de Nemours and Company Haskell Laboratory for Health and Environmental Sciences Elkton Road, P.O. Box 50 Newark, Delaware 19714-0050
WORK REQUEST NUMBERjUByj
SERVICE CODE NUMBERi H I
Page 1 of 40
^mpsny San%grf. CTo^^Eafh TSCACBt
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
CERTIFICATION
We, the undersigned, declare that this report provides an accurate evaluation of data obtained from this study.
Reviewed by;
'Paul M. Hinderiitcr, Ph.D. Postdoctoral Fellow
/A-/^-^'
Dale
Reviewed by;
(J^ibt^L ^
^fcg^^ // JudiA C. Stadler, PhJD.,
D.A.B.T.Dale '
Director
>6-^C-^OOf
Igmed by Study Director:
jl^X^A^ f (U[^ 'JCf/iIA^
CStaaffrSocienltRist <llay,B.A.0Date
2 -
-
Company Sanitised. Does not c-j.-iiam TSCA CBt
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
TABLE OF CONTENTS
Page
CERTIFICATION.........................................................................................................................!
LIST OF TABLES .........................................................................................................................4
LIST OF FIGURES .......................................................................................................................4
LIST OF APPENDICES...............................................................................................................4
STUDY INFORMATION .............................................................................................................5
STUDY PERSONNEL...................................................................................................................?
REASON
FOR
SUPPLEMENT
NO.
1 ........................................................................................8
SUMMARY....................................................................................................................................9
MATERIALS AND METHODS................................................................................................10
RESULTS AND DISCUSSION ..................................................................................................10
A. Liver Weights....................................................................................................................10
1. Test Substance......................................................;............,,...................................................................10 2. Positive Controls.................................................................................................................................... 10
B. Liver Fluorine Data,...........................................................................................................11 1. Positive Controls.................................................................................................................................. -11
2. Test Substance........................................................................................................................................11
CONCLUSIONS..........................................................................................................................11
TABLES........................................................................................................................................12
FIGURES......................................................................................................................................16
APPENDICES ..............................................................................................................................22
-3-
Company Sanitized. Does not contain TSCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
LIST OF TABLES
Page
1. MEAN BODY AND LIVER WEIGHTS.............................................................................................................13 2. MEAN LIVER FLUORINE LEVELS..................................................................................................................15 3. MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE..................................................15
LIST OF FIGURES
Page
1. COMPARISON OF MEAN RELATIVE LIVER WEIGHTS: TEST SUBSTANCE AND NEGATIVE
CONTROLS.........................;...............................................................................................................................17
2. COMPARISON OF MEAN RELATIVE LIVER WEIGHTS: TEST SUBSTANCE AND POSITIVE
CONTROLS.........................................................................................................................................................18
3. COMPARISON OF RELATIVE LIVER WEIGHT AND MEAN LIVER FLUORINE CONCENTRATION FOR H-23961 AND NEGATIVE CONTROLS...................................................................................................19
4. MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE..................................................20 5. COMPARISON OF MEAN BLOOD AND MEAN LIVER FLUORINE CONCENTRATION
NORMALIZED TO DOSE..................................................................................................................................21
LIST OF APPENDICES
Page
A. INDIVIDUAL FINAL BODY WEIGHTS, LIVER WEIGHTS, AND RELATIVE LIVER TO BODY
WEIGHT.............................................................................................................................................................^
B. INDIVIDUAL FLUORINE LEVELS ..................................................................................................................34
Company Sanitized. Does not contain TSCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
STUDY INFORMATION TEST SUBSTANCE:
Substance 11 li il iBB^^Bj
Synonyms/Codes.^* H-23961
Haskell Number: 23691
DuPont-2923 Supplement No. 1
POSITIVE CONTROL;
Substance Testa Synonyms/Codes: i--H-24019
Haskell Number:
Company Sanitized. Does not contain TSCA CB1
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
STUDY INFORMATION (Continued)
Compositjoi
DuPont-2923 Supplement No. 1
POSITIVE CONTROL;
Substance Tested:
Synonyms/Codes: H-24020
Haskell Number: 24020 Compositio
Known Impurities: Unknown
Sponsor:
E. I. du Pont de Nemours and Company Wilmington, Delaware 19898
U.S.A.
Study Initiated/Completed: April 30, 1999 / (see report cover page)
K-\
In-Life Initiated/Completed: May 30, 1999 / August 30, 1999
-6-
Company Sanitized. Does not contain TSCA CBi
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
STUDY PERSONNEL
Study Director: Management:
Primary Technician:
Carol Finlay, B.A. Judith C. Stadler, Ph.D., D.A.B.T. Richard P. Mathena
Liver Fluorine Data Analysis: Paul M. Hinderliter, Ph.D. Management: Matthew S. Bogdanffy, Ph.D., D.A.B.T.
Toxicology Report Preparation: Wanda F. Dinbokowitz
Laboratory Veterinarian: Wanda L. West, D.V.M., A.C.L.A.M.
-7-
Company Sanitized. Does not contain TSCA CB!
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
REASON FOR SUPPLEMENT NO. 1
The purpose of this supplement is to present the results from analysis of selected liver samples from rats treated with the test substance (H-23961), 2 positive controls (H-24019 and H-24020), and 2 negative controls (corn oil and corn oil/acetone).
-8-
Company Sanitized. Does not contain TSCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
SUMMARY
The objective of this study was to evaluate the potential for H-23961, when administered by gavage, to be absorbed and to accumulate in a mammalian system. Six groups of 5 male Crl:CD(SD)IGS BR rats each were given 1000 mg/kg/day of H-23961. The test substance was administered to one group of 5 rats for 5 consecutive days and to 5 groups for 10 days. On selected days (5,10, 13, 24, 52, 94) 5 rats per group were euthanized and the blood and livers were collected. Livers were weighed and those collected on study days 10,13, and 94 were analyzed for total fluorine. This supplement includes liver weight data and the results of total fluorine analyses in livers. Additionally, 2 negative controls, corn oil and corn oil/acetone (80:20), and 2 positive controls, H-24019 (10 mg/kg/day) and H-24020 (20 mg/kg/day), were tested and analyzed as described for H-23961.
The mean relative liver weights (liver/body weight) of rats dosed with the test substance, H-23961, were similar to the negative controls during the dosing and recovery periods. On day 10, the mean relative liver weight of rats dosed with the positive control H-24019 was up to 27% higher than the negative controls. By day 94, the mean relative liver weight was up to 28% higher than the negative controls. In rats given H-24020, the mean relative liver weight was up to 75% higher at day 10 than the negative controls. By day 94, the weights were similar.
The concentration of fluorine in the livers from rats dosed with the test substance, H-23961, was 18.43 fJtMequivalents on day 10 and 3.50 {tM equivalents on day 94. On day 10, mean /xM equivalent concentrations of fluorine in the livers from rats dosed with the positive control materials were approximately 275-fold (H-24019) and 60-fold (H-24020) greater than the fluorine concentration in livers from rats treated with the test substance. By day 94, the concentrations were approximately 340x and 3x the fluorine concentration in rats treated with H-23961.
The ftM equivalents of fluorine in the livers from rats dosed with the test substance were higher
than levels in the blood.
Under the conditions of this study, there was some absorption and retention of fluorine in the liver from rats dosed with H-23961. However, fluorine levels in the liver were significantly lower than levels in rats dosed with the positive control materials, H-24019 and H-24020. Liver
weights were not affected in rats dosed with the test substance.
9 -
-
Company Sanitized. Does net contain TSCA C81
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
MATERIALS AND METHODS
Blood and livers were collected on days 5,10,13,24,52, and 94. The livers were weighed.
Only the test day 10,13, and 94 livers were analyzed for total fluorine. These time points provided sufficient data to determine the accumulation and persistence of fluorine in the liver. See the original report for details of the analysis.
RESULTS AND DISCUSSION
A.
Liver Weights
(Table 1, Figures 1-3, Appendix A)
As with body weights, comparison of absolute liver weights was complicated by the fact that there was a difference in age on test day 1 between rats dosed with the test substance and those dosed with the positive or negative controls. The rats dosed with the test substance, H-23961, were older and heavier in weight than the corn oil negative control and H-24020 positive control rats, but younger and lighter in weight than the corn oiVacetone negative control and H-24019 positive control rats. Therefore, liver weights relative to body weight are presented for
comparison.
1.
Test Substance
The mean relative liver weights of rats dosed with the test substance, H-23961, were similar to the negative controls during the dosing and recovery periods.
2.
Positive Controls
The mean relative liver weight of rats dosed with one of the positive controls, H-24019, was 17% higher on day 10 than the liver weight of rats dosed with the test substance, H-23961. On days 13, 24, and 52 (recovery), the mean relative liver weights of rats dosed with H-24019 were 13-36% higher than the liver weights of rats dosed with H-23961. By test day 94 (end of recovery), the mean relative liver weight of rats dosed with H-24019 was 21% higher than the liver weight of rats dosed with H-23961. The mean relative liver weight of rats dosed with H-24020, the other positive control, was 60% higher on day 10 than the liver weight of rats dosed with H-23961. On days 13 and 24 (recovery), the mean relative liver weights of rats dosed with H-24020 were 60 and 33% higher than the liver weights of rats dosed with H-23961. On days 52 and 94, the weights were similar.
The mean relative liver weight of rats dosed with H-24019 was up to 27% higher at day 10 than the negative control groups. By day 94, the mean relative liver weight of rats dosed with H-24019 was up to 28% higher than the negative controls. The mean relative liver weight of rats dosed with H-24020 was up to 75% higher at day 10 than the negative controls. The mean
-10- Company Sanitized. Does not contain TSCA CBI
H-23961: Biopersistence Screening
DuPont-2923
10-Dose Oral Gavage Study in Rats__________________________________Supplement No. 1
relative liver weights of rats dosed with H-24020 began to decrease during the recovery period and were similar by test day 94 to the negative controls.
Therefore, liver weights of rats dosed with the test substance, H-23961, were not affected.
B.
Liver Fluorine Data
(Tables 2-3, Figures 3-5, Appendix B)
1.
Positive Controls
The positive controls were H-24019 and H-24020. The concentrations of fluorine in the livers on
day 10 from rats dosed with the positive control materials were 5045.85 and 1127.25 pM
equivalents for H-24019 and H-24020, respectively. At day 13, the liver concentrations were 4135.69 and 334.49 piM equivalents. By day 94, the concentrations were 1190.15 and 10.72 fJiM
equivalents.
2.
Test Substance
Levels of total fluorine in livers from rats dosed with the test substance, H-23961, were lower than the levels in livers from rats dosed with the positive control materials. The total fluorine concentration in the liver from rats dosed with H-23961 was 18.43 p.M equivalents at day 10, 11.89 /xM equivalent at day 13, and 3.50 /zM equivalents at day 94. For the positive control H-24019, the liver concentrations were approximately 275x higher (day 10) and approximately 340x higher (end of study) than H-23961. For H-24020, the liver concentration was approximately 60x higher (day 10) and approximately 3x higher (end of study).
The fJiM equivalents of fluorine in the livers from rats dosed with the test substance were higher
than levels in the blood.
CONCLUSIONS
Under the conditions of this study, there was some absorption and retention of fluorine in the liver from rats dosed with H-23961. However, fluorine levels in the liver were significantly lower than levels in rats dosed with the positive control materials, H-24019 and H-24020. Liver weights were not affected in rats dosed with the test substanc.
-11- Company Sanitized. Does not contain TSCA CBI
TABLES
12Company Sanitized. Does not contain TSCA CBI
Test Days 5 10 13 24 52 94
TABLE 1
MEAN BODY AND LIVER WEIGHTS (g)
CORN OIL (NEGATIVE CONTROL)
Absc)lute
Body Weight
Liver Weight
259.3
12.620
311.1
15.861
322.9
14.906
391.2
16.635
464.7
17.240
557.8
20.118
Mean Relative Liver Weight(% of Body Weight)
0.049 0.051 0.046 0.043 0.037 0.036
Test Days 5 10 13 24 52 94
CORN OIL:ACETONE (NEGATIVE CONTROL)
Absolute
Body Weight
Liver Weight
313.4
13.632
356.5
15.597
377.6
17.715
423.5
17.172
527.6
21.275
567.8
18.447
Mean Relative Liver Weight(% of Body Weight)
0.043 0.044 0.047 0.041 0.040 0.032
Test Days 5 10 13 24 52 94
H-24019 (POSITIVE CONTROL)
Absolute
Body Weight
Liver Weight
306.6
15.456
310.1
17.336
344.8
22.049
387.9
21.313
438.1
19.826
597.9
24.455
Mean Relative Liver Weight(% of Body Weight)
0.050 0.056 0.064 0.055 0.045 0.041
-13- Company Sanitized. Does not contain 7SCACB1
H-23961: B iopersistence Screening 10-Dose Oral Gavage-Study in Rats
DuPont-2923 Supplement No. 1
Test Days 5 10 13 24 52 94
TABLE 1 (Continued)
MEAN BODY AND LIVER WEIGHTS (g)
H-24020 (POSITIVE CONTROL)
A1^solute
Body Weight
Liver Weight
244.8
17.052
284.4
21.944
289.1
21.780
370.3
20.619
456.7
17.713
538.7
18.205
Mean Relative
Lrver Weight(% of Body Weight)
0.070 0.077 0.075 0.056 0.039 0.034
Test Days 5 10 13 24 52 94
H-23961 (TEST SUBSTANCE)
__B_o_d_y_W_e_igAhbt_s_o_l_uLtivee_r_W_e_ig_h_t __
264.9
11.821
306.4
14.729
336.7
15.488
381.7
15.991
502.0
19.891
561.7
18.957
Mean Relative Liver Weight(% of Body Weight)
0.045 0.048 0.046 0.042 0.040 0.034
Company Sanitized. Does not contain TSCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
TABLE 2 MEAN LIVER FLUORINE LEVELS
Test Days
10 13 94
Negzitive Controls
Corn Oil (ppm)
Corn Oil: Acetone
(ppm)
<0.2
<0.5
0.6"
I3
Positive Controls
H-24019 (ppm)
328.18 (19.3)" 269.02 (10.1) 77.56 (10.1)
H-24020 (ppm)
155.76 (29.2) 46.36 (10.7)
1.68 (0.3)
a One value. Four of the values were below the level of detection (LOD). b Standard deviation is in parentheses.
Indicates no value for this day.
Test Substance
H-23961
(ppm)
20.84 13.52
(2.7) (1.5)
4.12 (4.0)
TABLE 3
MEAN LIVER FLUORINE CONCENTRATION NORMALIZED TO DOSE
Test Days
10 13 94
Positive Controls
H-24019
H-24020
/iM F Equivalents
5045.85 (296.91)3
pM F Equivalents
1127.25 (211.37)
4135.69 (155.38)
334.49 (77.70)
1190.15 (156.05)
10.72 (2.14)
a Standard deviation is in parentheses.
Test Substance
H-23961
liM F Equivalents
18.43 (2.4)
11.89 (1.4) 3.50 (3.6)
-15Company Sanitized. Does not contain 7SCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
FIGURES
-16-
Company Sanitized. Does not contain TSCA CBI
[-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
FIGURE 1 COMPARISON OF MEAN RELATIVE LIVER WEIGHTS:
TEST SUBSTANCE AND NEGATIVE CONTROLS
Test Day
-17-
Company Sanitized. Does not co
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
FIGURE 2 COMPARISON OF MEAN RELATIVE LIVER WEIGHTS:
TEST SUBSTANCE AND POSITIVE CONTROLS
Test Day
-18-
Company Sanitized. Does not cont
3961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
FIGURES COMPARISON OF RELATIVE LIVER WEIGHT AND MEAN LIVER FLUORINE CONCEN
FOR H-23961 AND NEGATIVE CONTROLS
Day 10
Day 13
Day 94
Day 10
Day 13
El Corn Oil (Negative Control) Corn OiLAcetone (Negative Control) D H-23961 (Test Substance)
-19-
Company Sanitized. Does not contai
eo 83
:
8
3
"
i
i4
3
113
-
3
J i
.
Gao
SER
i
3
\
TE
SB OE Behe Te | }
sworeanba 4 wt
3961: Biopersistence Screening
10-Dose Oral Gavage Study in Rats
FIGURE 5 COMPARISON OF MEAN BLOOD AND MEAN LIVER FLUORINE CONCENTRATION NORMA
6000
5000
4000
3000
.
_S
"5 o" uj
2000
1000
Blood / Liver
Blood / Liver
Blood / Liver
-21-
Company Sanitized. Doss not co
H-23961: Biopersistence Screening 10-DoseOralGavage Study in Rats^
DuPont-2923 Supplement No. 1
APPENDICES
-22- Company Saniilzed. Does r.ot csssiffin TSCA. CB!
APPENDIX A Individual Final Body Weights, Liver Weights, and Relative Liver to Body Weight
-23-
Company Sanitized. Does no; contain TSCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
CORK1 OIL (NEGATIVE CONTROL)
INDIV:IDUAL FINAL BC>DY WEIGHTS (g),. LIVER WEIGHTS (cr), AND RELATIVE LF^ER TO BODY WE I GHT OF MALE RATS
Animal Number 627789
627801
627805
627810
627818
Final
Body Wfc.
247.7
240.1
283.7
265.0
260.2
GROUP I
Liver Wt. 11.428
12.216 14.081 13.395 11.981
Relative Liver to Body Wt. 0.046
0.051
0.050
0.051
0.046
Test Day
5
5 5 5
5
Animal Number 627793
627797
627799
627800 627808
Final
Body Wt. 283.5
324.2
294.7
331.3
321.8
GROUP II
Liver Wt.
15.292 15.803 14.285 16.344 17.580
Relative Liver to Body Wt.
0.054
0.049
0.048
0.049
0.055
Test Day
10 10 10 10 10
Animal Number 627796
627806
627807
627809
627816
Final
Body Wt. 322.7
320.3
305.2
336.2
330.2
GROUP III
Liver Wt. 13.404 15.413 14.935 14.967 15.811
Relative Liver to Body Wt. 0.042
0.048
0.049
0.045
0.048
Test Day
13
13 13 13
13
-24- Company Sanitized. Does not coniain TSCA CB1
H-23961: B iopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
CORKr OIL (NEGATIVE; CONTROL)
mm/IDUAL FINAL BC)DY WEIGHTS (g) , LIVER WEIGHTS (cr), AND
RELATIVE LP'\TER TO BODY WE:[GHT OF MALE RATS
Animal Number 627791
627794
627804
627812
627817
Final
Body Wt. 365.6
416.7
378.1
388.4
407.3
GROUP IV
Liver Wt. 15.371 19.105 15.326 16.775 16.600
Relative Liver to Body Wt. 0.042
0.046
0.041
0.043
0.041
Test Day
24 24 24 24
24
Animal Number 627792
627798
627813
627814
627815
Final
Body Wt. 496.8
517.3
416.8
386.9
505.9
GROUP V
Liver Wt. 16.359
19.293 15.234 14.358 20.958
Relative Liver to Body Wt.
0.033
0.037
0.037
0.037
0.041
Test Day
52 52 52 52
52
Animal Number 627795
627811
627819
627820
627821
Final
Body Wt. 485.0
511.6
653.1
618.0
521.5
GROUP VI
Liver Wt. 16.649 17.405 21.828 26.766 17.943
Relative Liver to Body Wt. 0.034
0.034
0.033
0.043
0.034
Test Day
94 94 94 94
94
-25- Company Sanitized. Does sasi oisoSaaa TSCA CBi
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
CORN OIL,:ACETONE (NEGA^['IVE CONTROL)
INDF/IDUAL FINAL BOiDY WEIGHTS (g),, LIVER WEIGHTS (cf), AND RELATIVE LP/ER TO BODY WEI GHT OF MALE RATS
Animal Number 625361
625363
625364
625380
625383
Final
Body Wt. 349.7
286.7
312.0
305.5
313.1
GROUP I
Liver Wt. 16.800 11.236 13.845 13.253 13.026
Relative Liver
to Body Wt. 0.048
0.039
0.044
0.043
0.042
Test Day
5 5 5 5
5
Animal Number 625355
625362
625367
625368 625378
Final
Body Wt.
333.6
332.9
363.8
386.7
365.4
GROUP II
Liver Wt. 14.409 14.363 16.139 17.745 15.328
Relative Liver to Body Wt.
0.043
0.043
0.044
0.046
0.042
Test Day
10 10 10 10 10
Animal Number 625357
625358
625370
625384
625385
Final
Body Wt. 405.6
340.7
407.0
357.1
377.6
GROUP III
Liver Wt. 20.091 12.954 21.654
16.520 17.355
Relative Liver to Body Wt. 0.050
0.038
0.053
0.046
0.046
Test Day
13
13
13 13 13
-26- Company Sanitized. Does not contain TSCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
CORN Oil,:ACETONE (NEGATIVE CONTROL) INDI^/IDUAL FINAL BC)DY WEIGHTS (g) , LIVER WEIGHTS (cr), AND
RELATIVE LPi/ER TO BODY WEI:GHT OF MALE RATS
Animal Number 625354
625365
625371 625376
625381
Final
Body Wt. 396.1
459.6
447.3
432.9
381.8
GROUP IV
Liver Wt. 16.383 18.313 17.859 19.168 14.135
Relative Liver to Body Wt. 0.041
0.040
0.040
0.044
0.037
Test Day
24 24 24 24 24
Animal Number 625356
625359
625360
625372
625374
Final
Body Wt.
533.7
530.3
555.4
506.2
512.3
GROUP V
Liver Wt. 20.498
22.901 23.312 21.287 18.378
Relative Liver to Body Wt. 0.038
0.043
0.042
0.042
0.036
Test Day
52 52 52
52 52
Animal Number 625353 625369
625373
625375
625377
Final
Body Wt. 565.3
514.8
673.7
588.8
496.6
GROUP VI
Liver Wt. 18.655 17.379 20.073 18.869 17.261
Relative Liver to Body Wt. 0.033
0.034
0.030
0.032
0.035
Test Day
94 94
94. 94 94
-27-
CcEipany SaufiadL Qaes aaS.essiMa. ISCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
H-2^1019 (POSITIVE CONTROL)
INDB/TDUAL FINAL BODY WEIGHTS (g) , LIVER WEIGHTS (cI), AND RELATIVE LI\^ER TO BODY WEI GHT OF MALE RATS
^
Animal Number 625322 625323 625336 625343 625349
Final
Body Wt. 329.0
298.0
318.1
294.0
293.7
GROUP I
Liver Wt.
16.409 14.830 16.545 13.809 15.685
Relative Liver to Body Wt.
0.050
0.050
0.052
0.047
0.053
Test Day
5 5 5 5 5
Animal Number 625320
625330
625332
625341
625350
Final
Body Wt. 312.1
310.1
318.3
325.6
284.3
GROUP II
Liver Wt. 18.845 16.343 17.528 18.254 15.709
Relative Liver to Body Wt. 0.060
0.053
0.055
0.056
0.055
Test Day
10 10 10
10 10
Animal Number 625321
625327
625342
625345
625348
Final
Body Wt. 371.2
355.3
324.4
336.9
336.4
GROUP III
Liver Wt. 22.322 22.259 20.718 24.403 20.541
Relative Liver to Body Wt. 0.060
0.063
0.064
0.072
0.061
Test Day
13 13 13 13
13
-28- Company Sanitized. Does not contain TSCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
H-2-4019 (POSITIVE CONTROL)
INDI\^IDUAL FINAL BOIDY WEIGHTS (g) , LIVER WEIGHTS (cr), AND
RELATIVE LI1/ER TO BODY WEI GHT OF MALE RATS
Animal
Number 625325
625328
625338
625340
625352
Final
Body Wt. 381.3
423.9
339.9
419.0
375.3
GROUP IV
Liver Wt. 21.479 22.100 18.018 23.131 21.835
Relative Liver
to Body Wt. 0.056
0.052
0.053
0.055
0.058
Test Day
24 24
24 24 24
Animal Number 625324
625329 625333
625334
625344
Filial
Body Wt.
447.4
498.1
427.4
426.5
391.0
GROUP V
Liver Wt. 20.900 20.911 20.508 19.144 17.666
Relative Liver to Body Wt.
0.047
0.042
0.048
0.045
0.045
Test Day
52 52 52
52 52
Animal
Number 625326
625335
625346 626347
625351
Final
Body Wt. 577.5
579.5
556.9
638.9
636.8
GROUP VI
Liver Wt. 23.749 21.548 23.945 27.416 25.615
Relative Liver to Body Wt.
0.041
0.037
0.043
0.043
0.040
Test Day
94
94 94 94 94
-29- Company Sanitized. Does not contain TSCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
H-2.4020 (POSITIVE CONTROL)
INDI^/IDUAL FINAL BCDY WEIGHTS (g),, LIVER WEIGHTS ( g), AND
RELATIVE LF/ER TO BODY WEI GHT OF MALE RATS
Animal Number 627756
627767
627771
627773
627777
Final
Body Wt. 237.5
248.6
239.6
262.3
236.0
GROUP I
Liver Wt. 15.360 19.033 16.968 17.629 16.268
Relative Liver to Body Wt. 0.065
0.077
0.071
0.067
0.069
Test Day
5 5 5 5
5
Animal
Number 627768
627774 627776
627782 627785
Final
Body Wt. 293.5
338.2
254.4
268.2
267.9
GROUP II
Liver Wt. 22.536 27.332 18.821 20.172 20.857
Relative Liver to Body Wt. 0.077
0.081
0.074
0.075
0.078
Test Day
10 10
10
10 10
Animal Number 627758
627763
627764
627787
627788
Final
Body Wt.
308.7
285.8
306.7
234.9
309.4
GROUP III
Liver Wt. 26.021 22.123 21.526 16.498 22.730
Relative Liver
to Body Wt. 0.084
0.077
0.070
0.070
0.073
Test Day
13 13 13
13 13
-30- Company Sanitized. Does not contain TSCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
H-2 4020 (POSITIVE CONTROL)
INDF^IDUAL FINAL BC)DY WEIGHTS (g) , LIVER WEIGHTS ( g), AND
RELATIVE LI1^ER TO BODY WE I ;GHT OF MALE RATS
Animal
Number 627759
627761
627770
627779
627786
Final
Body Wt. 380.1
359.4
379.8
406.2
326.1
GROUP IV
Liver Wt. 22.707 19.579 19.540 24.858 16.410
Relative Liver to Body Wt. 0.060
0.054
0.051
0.061
0.050
Test Day
24
24 24 24 24
Animal Number 627757
627760
627765
627772
627781
Final
Body Wt.
436.7
456.5
455.6
513.5
421.0
GROUP V
Liver Wt. 16.899 18.240
16.505 20.225 16.695
Relative Liver to Body Wt. 0.039
0.040
0.036
0.039
0,040
Test Day
52 52 52
52 52
Animal Number 627762 627769
627775
627778
627783
Final
Body Wt. 528.6
609.6
552.8
445.3
557.2
GROUP VI
Liver Wt.
17.732 19.324 17.296 15.628 21.044
Relative Liver to Body Wt. 0.034
0.032
0.031
0.035
0.038
Test Day
94 94 94 94 94
-31
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
H-2 3961 (TEST SUB STANCE)
INDI^/IDUAL FINAL BOE)Y WEIGHTS (g) ,. LIVER WEIGHTS (gr), AND RELATIVE LIV;ER TO BODY WE I GHT OF MALE RATS
Animal Number 626876
626877
626885
626889
626890
Final
Body Wt. 262.6
278.2
245.9
268.9
268.9
GROUP I
Liver Wt. 12.535 12.834 10.960 11.468 11.306
Relative Liver to Body Wt. 0.048
0.046
0.045
0.043
0.042
Test Day
5 5
5 5 5
Animal Number 626871
626872
626875
626882
626888
Final
Body Wt. 309.0
318.1
315.1
325.1
264.8
Animal Number 626868
626879
626886
626887
626891
Final
Body Wt. 366.9
320.6
319.9
329.9
346.3
GROUP II
Liver Wt. 16.809
15.772 15.102 14.461 11.499
Relative Liver to Body Wt. 0.054
0.050
0.048
0.044
0.043
Test Day
10 10
10
10 10
GROUP III
Liver Wt. 16.841 15.748 14.966
13.393 17.845
Relative Liver to Body Wt. 0.046
0.049
0.047
0.041
0.052
Test Day
13 13
13 13 13
-32- Company Sanitized. Does not corAain TSCA CB!
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
H-:23961 (TEST SUI3STANCE)
INDF/IDUAL FINAL BC>DY WEIGHTS (g) , LIVER WEIGHTS (c[), AND RELATIVE LF/ER TO BODY WE][GHT OF MALE RATS
Animal Number 626864
626865
626873
626894
626895
Final
Body Wt. 390.7
351.8
424.7
380.8
360.6
GROUP IV
Liver Wt. 16.059
14.379 18.570 15.501 15.449
Relative Liver to Body Wt. 0.041
0.041
0.044
0.041
0.043
Test Day
24 24 24
24 24
Animal Number 626867
626880
626881
626884
626892
Final
Body Wt. 478.7
470.8
533.9
507.8
518.8
GROUP V
Liver Wt. 17.371 19.473 21.007 21.287 20.319
Relative Liver to Body Wt. 0.036
0.041
0.039
0.042
0.039
Test Day
52 52
52
52 52
Animal Number 626866
626869
626874
626893
626896
Final
Body Wt. 565.5
507.0
654.5
539.5
541.8
GROUP VI
Liver Wt. 19.198 17.216 22.444 16.143 19.786
Relative Liver to Body Wt. 0.034
0.034
0.034
0.030
0.037
Test Day
94 94
94 94
94
-33-
LTSCA.CBS
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
APPENDIX B
Individual Fluorine Levels
-34- Cosnpeny Sare?tze& Does nal sanlain 7SOA CK
%
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
Terms: Active % Active
TERMS AND CALCULATIONS
Mol Wt Active
Formulation Dose % F in Active
MolWtF
Compound Calculations:
Dose Active (mg/kg)
The mg of fluorine containing compound administered per kg of animal body weight.
= (% active/100) x Formulation Dose
Dose Active (mmole/kg)
The mmole of fluorine containing compound administered per kg of
animal body weight
= dose [mg/kg] / Mol Wt Active [mg/mmol]
Dose F (mg/kg)
The mg Fluorine administered per kg of animal body weight = (% F in active/100) x Dose Active [mg/kg]
Dose F (mmol/kg)
The mmole of fluorine administered per kg of animal body weight = Dose F [mg/kg] / Mol Wt F [mg/mmol]
Molar Ratio (Active/F)
The moles of fluorine containing compound per mole of fluorine = Dose Active [mmol/kg] / Dose F [mmol/kg]
Formulation Dose Normalization Factor
The formulation dose that would be required to administer the amount of active needed to achieve the normalized dose
= (Normalized dose of Active [mmol/kg] / Dose Active [mmol/kg]) x Formulation Dose
-35- Cci^paay SaEutizad. Does tiotcaatsiti TSCA CBI
TERMS AND CALCULATIONS
Individual Animal Measurement:
ppm F in liver
The ppm fluoride measured in liver
Individual Animal Calculations:
ppm F in Liver minus Bkg 0.2 ppm
ppm F in Liver normalized to 0.1 mmol/kg Dose
The ppm fluoride measured in liver minus the background fluoride measured in control animal liver. In this case the value was established at 0.2 ppm.
The ppm fluoride minus background that would be expected if the active dose was 0.1 mmol/kg instead of the actual active dose. This assumes linearity between administered dose and liver fluorine levels, but is needed because different doses of active were used in the study.
= (0.1 [mmol/kg] / Active dose [mmol/kg]) x (ppm F in liver
minus background)
j^molar equivalents of active in liver
The /imolar [/zmol/L] concentration of fluorine containing compound
in liver based on the ppm fluorine in liver normalized to 0.1 mmol/kg active dose. This assumes that all liver fluorine is derived from the fluorine-containing component in the formulation. Note: 1 ppm -
Img/L = (Normalized ppm [mg/L] fluorine in liver / Mol Wt F
[mg/mmol]) x molar ratio active/F [mmol active/mmol F] x 1000 ^imol/mmol
-36-
CoEnpany Sanitized. Does ncf cssiisaa TSCA CBS
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
DuPont-2923 Supplement No. 1
FACTORS INFLUENCING INTERPRETATION OF KINETIC ANALYSIS
Considerations:
- The data used for kinetic analysis was from a limited screen and extrapolation should be done
cautiously.
- Sample size is low - Analytical data used without validation - Steady-state not reached - Terminal phase may not be reached - Some compounds are mixtures of fluorinated compounds - Different active and formulation doses were used - Different vehicles were used to deliver formulations - Each compound may have very different potency for producing toxicity
Assumptions: (May or may not be justified in all cases)
- Liver fluorine concentrations are linear with respect to dose - Analytical method is appropriate for all types of compounds - Elimination kinetics can be determined based on total fluorine rather than on concentrations of
individual components - Background Fluorine is 0.2 ppm - % F data is the % Fluorine of the active (Fluorine containing component(s) in the formulation) - Molecular weight is the molecular weight of the active component in the formulation
-37- CGEipar.g Sanitized. DoasnatGantam TSCACBi
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
Data for H- 24019
DuPont-2923 Supplement No. 1
Given:
Mol Wt. Active (g/mole):
497
Formulation Dose (mg/kg):
10
% Active (F Containing) in Formulation: 100
% P in Active:
65
Mol Wt. F (g/mol):
19
Calculated Values: Dose Active (mg/kg): Dose Active (mmole/kg):
Formulation Dose Normalization Factor:
10 0.020 49.7
Dose F (mmol/kg):
0.342
Molar Ratio (Active/F): 0.059
Dose F (mg/kg):_____6.5
Rat Number
Test Day Sample
ppmF
in
Liver
Group II
625320
10
625330
10
625332
10
625341
10
625350
10
319.4 355.4 338.4 305.0 322.7
Group III
625321
13
625327
13
625342
13
625345
13
625348
13
255.9 275.3 277.9 260.4 275.6
Group VI
625326
94
625335
94
625346
94
625347
94
625351
94
79.8 89.6 73.8 62.5 82.1
ppm F in Liver
Minus Bkg 0.2 ppm
319.2 355.2 338.2 304.8 322.5
255.7 275.1 277.7 260.2 275.4
79.6 89.4 73.6 62.3 81.9
ppm F in Liver Normalized to 0.1 mmoles/kg
Dose
^molar Equivalents of Active in
Liver
1586.42 1765.34 1680.85 1514.86 1602.83
4910.77 5464.62 5203.08 4689.23 4961.54
1270.83 1367.25 1380.17 1293.19 1368.74
3933.85 4232.31 4272.31 4003.08 4236.92
395.61 444.32 365.79 309.63 407.04
1224.62 1375.38 1132.31 958.46 1260.00
-38-
Company Sanitized. Does not contain TSCA CBI
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
Data for H- 24020
DuPont-2923 Supplement No. 1
Given:
Mol Wt. Active (g/mole):
426
Formulation Dose (mg/kg):
20
% Active (F Containing) in Formulation: 100
% F in Active:
69
Mol Wt. F (g/mol):
19
Calculated Values: Dose Active (mg/kg): Dose Active (mmole/kg): Formulation Dose Normalization Factor:
20 0.047 42.6
Dose F (mmol/kg):
0.726
Molar Ratio (Active/F): 0.065
Dose F (mg/kg):_____13.8
Rat Number
Test Day Sample
ppmF
in
Liver
Group II
627768
10
182.5
627774
10
109.0
627776
10
174.0
627782
10
147.5
627785
10
165.8
Group III
627758
13
627764
13
627787
13
627763
13
627788
13
61.5 40.5 33.3 51.3 45.2
Group VI
627778
94
627783
94
627762
94
627775
94
627769
94
1.9 - 1.2
1.9 1.6 1.8
ppm F in Liver
Minus Bkg 0.2 ppm
182.3 108.8 173.8 147.3 165.6
61.3 40.3 33.1 51.1 45.0
1.7 1.0 1.7 1.4 1.6
ppm F in L iver Normalizedto 0.1 mmoles/kg
Dose
388.30 231.74 370.19 313.75 352.73
130.57 85.84 70.50
108.84 95.85
3.62 2.13 3.62 2.98 3.41
/imolar Equivalents of Active in
Liver
1321.01 788.41 1259.42 1067.39 1200.00
444.20 292.03 239.86 370.29 326.09
12.32 - 7.25
12.32 10.14 11.59
-39- Company SanifzecL Does not <^n. TSQA OK
H-23961: Biopersistence Screening 10-Dose Oral Gavage Study in Rats
Data for H-23961
DuPont-2923 Supplement No. 1
Given:
Mol Wt. Active (g/mole):
27500
% F in Active:
40
Formulation Dose (mg/kg):
1000
Mol Wt. F (g/mol):
19
% Active (F Containing) in Formulation: 28
Calculated Values: Dose Active (mg/kg): Dose Active (mmole/kg): Formulation Dose Normalization Factor:
280 0.010 9821.4
Dose F (mmoVkg):
5.895
Molar Ratio (Active/F): 0.002
Dose F (mg/kg):_____112
Rat Number
Test Day Sample
ppmF
in
Liver
Group II
626871
10
626872
10
626875
10
626882
10
626888
10
19.6 22.8 20.8 17.1 23.9
Group III
626868
13
626879
13
626886
13
626887
13
626891
13
15.7 13.4 12.4 14.3 11.8
Group VI
626866
94
11.3
626869
94
2.5
626874
94
1.6
626893
94
2.4
626896
94
2.8
ppmF in Liver
Minus Bkg 0.2 ppm
19.4 22.6 20.6 16.9 23.7
15.5 13.2 12.2 14.1 11.6
11.1 2.3 1.4
2.2
'
2.6
ppm F in Liver Normalized to 0.1 mmoles/kg
Dose
190.54 221.96 202.32 165.98 232.77
152.23 129.64 119.82 138.48 113.93
109.02 - 22.59
13.75 21.61 25.54
/imolar Equivalents of Active in
Liver
17.32 20.18 18.39 15.09 21.16
13.84 11.79 10.89 12.59 10.36
9.91 2.05 1.25 1.96 2.32
-40- Cosapany San.^sd.. Dass nctcoasam TSCA CBI